Discounted Cash Flow

Alterity Therapeutics Ltd. ADR

ATHE · Based on 10 years of SEC filings · Converted from AUD to USD (503 ordinary shares per ADR)

⚠ Cash flow predictability 54/100 (moderate) — FCF YoY std dev 52%, net income 55% (full history)

DCF estimate unavailable — No positive free cash flow in recent history — company has not generated positive FCF

Average annual growth rates

Metric 10-Year 5-Year 3-Year
Sales
Free Cash Flow
Average (FCF & NI)
Net Income
Dividends

Average annual growth is the mean year-over-year change across each period.

Endpoint CAGR (better for long term trend)

Metric 10-Year 5-Year 3-Year
Sales
Free Cash Flow
Average (FCF & NI)
Net Income

Endpoint CAGR is the compound annual rate from the first to last year in each period.

Projections use average year-over-year growth. Change this in Settings.

Projected growth rate

Free cash flow growth
10-year: — 5-year: — 3-year: —
Averaged growth (FCF & NI)
10-year: — 5-year: — 3-year: —
Net income growth
10-year: — 5-year: — 3-year: —
Sales growth (not added to calculations)
10-year: — 5-year: — 3-year: —

Click a greyed-out slider to switch metrics. Slide between the 10-year, 5-year, and 3-year historic growth rates for FCF, net income, or their average.

%
%

Historical inputs (10 fiscal years)

YEAR Sales Net Income Free Cash Flow Net Margin EPS (diluted)
2016
2017 $-5.4m $-4.2m $-1.41
2018 $144.5k $-5.9m (-9.6%) $-4.5m (-6.5%) -4108.8% $-1.55 (-9.9%)
2019 $78.0k (-46.0%) $-8.9m (-49.3%) $-10.0m (-123.4%) -11367.3% (-176.7%) $-2.00 (-29.0%)
2020 $12.3k (-84.2%) $-9.7m (-9.1%) $-6.8m (32.4%) -78616.6% (-591.6%) $-1.50 (25.0%)
2021 $14.9k (20.8%) $11.0m (213.8%) $-12.5m (-83.8%) 74044.1% (194.2%) $-0.90 (40.0%)
2022 $1.8k (-87.9%) $9.2m (-16.1%) $-8.9m (28.8%) 513061.5% (592.9%) $-0.53 (41.1%)
2023 $11.8k (556.4%) $9.9m (7.5%) $-14.4m (-62.4%) 84001.7% (-83.6%) $-0.57 (-7.5%)
2024 $192.9k (1533.1%) $-13.7m (-238.2%) $-9.1m (37.1%) -7107.3% (-108.5%) $-0.52 (8.8%)
2025 $320.7k (66.3%) $-8.7m (36.7%) $-8.2m (9.2%) -2706.7% (61.9%) $-0.19 (63.5%)

Base FCF: (latest fiscal year)

Discount rate: %

Terminal growth:

Projection period: years

Alt A decline yrs:

Alt B total yrs:

SEC filings report in AUD. Values above are converted to USD for comparison with the US-listed share price.

Projected cash flows

Year Projected cash flow Discount Factor Present Value

PV of projected FCF:

Terminal FCF:

Terminal value:

PV of terminal value:

Enterprise value (DCF):

DCF price per share:

Current price:

Alternative DCF Models

Model Fair Value Upside PV(FCFs) PV(Terminal) Total Years
Standard (10yr→TV) 10 + TV
Alt A (Gradual Decline)
Alt B (30yr Hard Stop) N/A

This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.

+ 10YR Financials Balance Sheet (10YR) Cash Flow (10YR) DCF Model

No positive free cash flow in recent history — company has not generated positive FCF

Once the company meets all DCF eligibility criteria (sufficient history, profitability, growth trends), an estimate will become available automatically. No action is needed.